Transcatheter Closure of Atrial Septal Defects with the STARFlex Device: Early Results and Follow‐Up

Abstract

The STARFlex device seems to offer better results than the CardioSEAL, with significantly lower rates of residual shunts and arm fractures.

Percutaneous ASD Closure in a Large Australian Series: Short- and Long-Term Outcomes

“…There were three different devices used in this study in which successful transcutaneous closure has been previously observed [2][3][4]: STARFLEX (NMT Medical Boston, MA, USA), a modified version of the CardioSEAL (CS) double umbrella device, which has the addition of a self centering mechanism; Helex (W.L. Gore & Associates Inc., Flagstaff, AZ, echocardiogram (TOE) where indicated, to evaluate the shunt and its surrounding rims as well as to look for any associated cardiac abnormalities.…”

A biodegradable device (BioSTAR™) for atrial septal defect closure in children

“…long sheath [17,18], monitored by fluoroscopy and intracardiac echocardiography (ICE). The device was soaked in a normal saline solution (5 min) to hydrate the collagen discs, which had been dehydrated for packaging and transport.…”

Patent foramen ovale closure with the Intrasept occluder: Complete 6–56 months follow‐up of 247 patients after presumed paradoxical embolism

“…More contemporary devices for closure of interatrial communications have improved compared to older occluders. Advancements include a simpler deployment technique involving only venous access, higher complete closure rates, eradication of wire fractures, and reduction of device-related thrombus formation [2,7,11,12]. However, structural factors such as atrial septal aneurysms (ASA), a large discrepancy in thickness between septum primum and septum secundum, as well as long PFO tunnels may potentially lead to a mismatch between the individual anatomy and the technical design of the device.…”